Seattle Genetics (SGEN) on the move as FDA has approved its lymphoma drug
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Join SI Premium – FREE
Seattle Genetics (Nasdaq: SGEN) on the move as FDA has approved its lymphoma drug
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- FDA grants fast track status to Rein Therapeutics drug for lung fibrosis
- FDA grants Nuvation Bio fast track status for brain cancer drug
Create E-mail Alert Related Categories
FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
